Moderna investors who bought the stock a year ago watched the shares soar to 703%, and now one of Wall Street’s biggest banks is telling them it’s time to sell.
The question of who’s right will likely define one of the most dramatic biotech stories of 2026.
In a note shared with TheStreet, Citi downgraded Moderna to Sell from Neutral on Sept. 30, 2026, raising its price target to $80 from $60, while the stock trades well above $200.
That’s not a minor adjustment. It implies roughly 60% downside from current levels.
The catalyst for the entire run was a single announcement in August 2026. Moderna’s personalized mRNA cancer vaccine, developed with Merck, met its Phase 3 endpoints in a melanoma trial, Merck reported.
The news triggered a 177% single-session surge. In fact, that was the biggest one-day gain for any S&P 500 stock in 25 years, according to The Wall Street Journal.
In biotech, moments like that are genuinely historic. They’re also where valuation can get completely untethered from reality. Geoff Meacham, head of healthcare research at Citi, is arguing that it has.
ALSO READ: Moderna Inc. Latest News and Stories
Why Citi is calling time on Moderna’s rally
Meacham’s downgrade rests on a specific valuation argument, and it’s worth following the math precisely.
Even assuming 100% probability of success for Moderna’s lead cancer programs — an assumption no serious analyst would actually make — Citi’s net present value analysis supports only around $100 per share, according to the note shared with TheStreet. The stock is trading more than 50% above that level.
To justify a price around $200, Moderna would need approximately $26 billion in annual cancer sales, of which $13 billion would go to Moderna itself, according to the note.
Citi’s own forecast is roughly one-seventh of that figure. That gap is the distance between a reasonable bull case and a scenario that requires near-total market dominance in oncology.
More Healthcare/Health:
- One IRA withdrawal can triple your Medicare premium
- UnitedHealth’s earnings comeback hides a risk Wall Street can’t price
- Medicare’s new $50 GLP-1 deal has a catch
“We struggle to justify the valuation through public-company comparisons or pipeline NPV,” Meacham wrote in the note. He pointed to a specific comparison: Moderna’s market cap of approximately $80 billion now approximates Regeneron’s, despite materially lower expected revenue and earnings.
I find that comparison telling. Regeneron has Eylea, Dupixent, Libtayo — a portfolio of approved products generating billions in annual revenue.
Moderna’s cancer franchise currently rests on one drug that recently passed Phase 3 interim analysis without disclosing the actual numerical results.
Investors are pricing Moderna as if those results, when disclosed, will be transformative across multiple tumor types.
Meacham cautions that melanoma, while meaningful, may not validate the technology broadly — it’s a cancer that already responds well to immunotherapy, which limits how much the mRNA approach can be credited for the efficacy.
On Aug. 5, the U.S. Food and Drug Administration (FDA) approved Moderna’s mRNA-based seasonal flu vaccine for adults 50 and older.
What the underlying Moderna business actually looks like
Strip away the cancer vaccine excitement, and Moderna is operating from a financially fragile position.
Q2 2026 revenue was $145 million. That’s barely above the $142 million in the same quarter a year ago, according to Moderna’s Q2 fiscal 2026 report. GAAP net loss was $800 million. EPS was negative $1.97.
The same Q2 statement reports that Moderna reiterated its full-year 2026 revenue growth target of up to 10%. That implies roughly $3 billion to $3.5 billion in annual revenue at current COVID vaccine run rates — a fraction of what an $80-plus billion market cap would typically require.
Related: Moderna just got a signal investors can’t ignore
The pipeline does offer real reasons for optimism. On Aug. 5, the U.S. Food and Drug Administration (FDA) approved mFLUSIVA. That’s Moderna’s mRNA-based seasonal flu vaccine for adults 50 and older, making it the company’s fifth approved product and the first mRNA-based influenza vaccine approved by the FDA, according to Moderna.
That’s a legitimate commercial milestone. Intismeran, the personalized cancer vaccine, is being tested across nine Phase 2 and Phase 3 trials in melanoma, lung cancer, bladder cancer, and renal cell carcinoma.
Five-year Phase 2b melanoma data presented at ASCO showed a 49% reduction in risk of recurrence or death compared to Keytruda alone, Merck reported.
That’s a genuinely impressive clinical result. The question Meacham is asking is whether it justifies the leap from impressive Phase 2 data to a valuation that implies blockbuster success across every tumor type.
His answer is no, not yet.
The risk-reward Citi says investors need to understand
Moderna is now the second-best-performing S&P 500 stock year to date, according to Slickcharts. Only SanDisk has outperformed it in 2026. The one-year return is at 703% as of writing, according to Yahoo Finance.
Stocks that move like that in a single year carry a particular kind of risk: the risk that the good news is already reflected in the price, and that any disappointment — a weaker-than-expected treatment effect, slower-than-expected expansion across tumor types, or a competitor advancing a similar approach — gets priced in with equal severity in the other direction.
Meacham explicitly described the current risk-reward as “negatively skewed.” Moderna’s Analyst Day is scheduled for Nov. 12. That event will be closely watched as the market tries to determine whether the rally was prescient or premature.
Meacham’s downgrade suggests he thinks it was premature. The 703% move in 1-year return means the burden of proof just got a lot heavier.
